Patents by Inventor Miki Aihara
Miki Aihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240216389Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: March 13, 2024Publication date: July 4, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki Aihara, Shizuo Kinoshita
-
Patent number: 11957691Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: GrantFiled: September 15, 2021Date of Patent: April 16, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
-
Publication number: 20220241293Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: September 15, 2021Publication date: August 4, 2022Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki Aihara, Shizuo Kinoshita
-
Patent number: 11147821Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: GrantFiled: December 19, 2018Date of Patent: October 19, 2021Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
-
Patent number: 11013746Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: GrantFiled: January 17, 2019Date of Patent: May 25, 2021Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
-
Publication number: 20190374549Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: January 17, 2019Publication date: December 12, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
-
Publication number: 20190117666Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: December 19, 2018Publication date: April 25, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
-
Publication number: 20170239265Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: May 5, 2017Publication date: August 24, 2017Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
-
Publication number: 20170196877Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: March 29, 2017Publication date: July 13, 2017Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
-
Patent number: 9669075Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: GrantFiled: November 9, 2015Date of Patent: June 6, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
-
Patent number: 9636382Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: GrantFiled: May 30, 2013Date of Patent: May 2, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
-
Injectable depot formulation comprising optically active tolvaptan and process of producing the same
Patent number: 9597283Abstract: This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same.Type: GrantFiled: December 27, 2013Date of Patent: March 21, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki Kaneko, Takakuni Matsuda, Kenichi Miyata, Kai Suzuki, Hiroyuki Fujiki, Shizuo Kinoshita, Koji Ohmoto, Miki Aihara -
Publication number: 20160250222Abstract: The present invention provides a combined drug for an injectable depot formulation having a superior effect of preventing and/or treating polycystic kidney disease. More specifically, the present invention relates to a drug for preventing and/or treating polycystic kidney disease, which is an injectable depot formulation comprising a particle containing tolvaptan or a prodrug thereof and a somatostatin analogue. The present invention also relates to a method for preventing and/or treating polycystic kidney disease using the drug.Type: ApplicationFiled: October 14, 2014Publication date: September 1, 2016Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki AIHARA, Katsuji HATTORI, Koji OHMOTO, Takakuni MATSUDA, Daiki KANEKO
-
Publication number: 20160058841Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: November 9, 2015Publication date: March 3, 2016Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
-
INJECTABLE DEPOT FORMULATION COMPRISING OPTICALLY ACTIVE TOLVAPTAN AND PROCESS OF PRODUCING THE SAME
Publication number: 20150352041Abstract: This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same.Type: ApplicationFiled: December 27, 2013Publication date: December 10, 2015Inventors: Daiki KANEKO, Takakuni MATSUDA, Kenichi MIYATA, Kai SUZUKI, Hiroyuki FUJIKI, Shizuo KINOSHITA, Koji OHMOTO, Miki AIHARA -
Publication number: 20150141338Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: May 30, 2013Publication date: May 21, 2015Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
-
Patent number: 5637597Abstract: The present invention provides agents for inhibiting production of interleukin-8 and for inhibiting granulocytes activation as well as novel method for curing inflamatory diseases. The agents for inhibiting production of interleukin-8, and for inhibiting granulocytes activation and for curing inflammatory diseases, which contains as an active ingredient, a carbostyril derivative represented by the general formula (I): ##STR1## where R is as described in the specification.Type: GrantFiled: June 7, 1995Date of Patent: June 10, 1997Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Takahide Matsuda, Shigeru Owada, Hiroshi Muta, Miki Aihara, Hisao Takizawa, Ken-ichi Imagawa, Mikio Kikuchi